TET2 and acute myeloid leukemia: <blockquote type=”cite”> <div> <div> <div> Combined TET2 and TP53 loss collaborate to promote acute myeloid leukemia development and generate a targetable vulnerability through upregulation of TIGIT ligands on malignant cells.